RECHERCHE :   Cancers du poumon - cancers thoraciques
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
Amgen 20160323: A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
cancer du poumon à petites cellules
I
CHUV
Amgen 20190009: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Vs Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
III
CHUV, HUG
BEAT-meso/ETOP 13-18: A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
Mésothéliome pleural malin
III
CHUV
BMS CA209-73L: A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer
cancer du poumon non à petites cellules localement avancé n’ayant jamais été traité
III
CHUV
BMS CA224-048: A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Tumeurs solides (Mélanome, Cancer du poumon non à petites cellules (NSCLC))
I, II
CHUV
CACZ885T2301: A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
Cancer bronchique non à petites cellules complètement réséqué, stade II à IIIA et IIIB
III
HUG
CHUV-DO-PART-2016: Study to Evaluate the Benefit of a High Frequency Ventilation System During Lung or Breast Cancer Radiotherapy Treatment
Cancer du sein, du poumon ou métastases pulmonaires
II
CHUV
ETOP 15-19: A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR-mutant NSCLC with acquired resistance
EGFR-mutant NSCLC with acquired resistance
II
HUG
CHESS/ETOP 14-18: A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic nonsmall cell lung cancer
Synchronous oligo-metastatic non small cell lung cancer
II
CHUV, HUG
IMpower030/GO40241: A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non−Small Cell Lung Cancer
Cancer du poumon (NSCLC)
III
CHUV
IOV-COM-202: A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors
Tumeurs solides
II
CHUV
Merck 3475-495 : A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-Based Combination Therapy for Advanced Non- Small Cell Lung Cancer
Advanced Non- Small Cell Lung Cancer
II
HUG
MK3475-867: A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
Medically inoperable NSCLC Stages I and IIA
III
HUG
NIVOTHYM/EORTC-1525: Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy
Cancer du thymus
II
CHUV
RACIN, A phase I study of the combination of nivolumab associated with low-dose radiation, aspirin/ celecoxib and either ipilimumab or low-dose cyclophosphamide, followed by nivolumab maintenance, in patients with advanced, TIL-negative solid tumors
Tumeurs solides
I
CHUV
SAKK 19/18: Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer (SQCLC) overexpressing FGFR mRNA A multicenter, single arm phase II trial
Advanced pretreated squamous-cell non-small cell lung cancer overexpressing FGFR mRNA
II
HUG
SAKK 19/17 : First line durvalumab in patients with PD-L1 positive, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial
PD-L1 positive advanced Non Small Cell Lung Cancer
II
HUG
SAKK16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) NSCLC. A multicenter phase II trial.
resectable stage III(N2) NSCLC
II
HUG
Skyscraper-01/GO41717: A phase III, randomized, double-blinded, placebo-controlled study of tiragolumab, an anti-TIGIT antibody, in combination with atezolizumab compared with placebo in combination with atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer
cancer du poumon non à petites cellules non traité de stade avancé inopérable ou métastatique
III
CHUV
Skyscraper-02/GO41767: A phase III, randomized, double-blinded, placebo-controlled study of atezolizumab plus carboplatin and etoposide with or without tiragolumab (anti-TIGIT antibody) in patients with untreated extensive-stage small cell lung cancer
cancer du poumon à petites cellules non traité de stade avancé
III
CHUV
CHUV-DO-0012-SolTIL-2018 - Phase Ib Study To Assess The Feasibility And Safety Of Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes In Advanced Solid Tumors
Tumeurs solides
I
CHUV